As a long-term holding, Pfizer should benefit from demographic trends driving increased healthcare spending globally. The ...

The stock's rise snapped a three-day losing streak.

Pfizer Inc. and Albert Bourla got the upper hand in an early skirmish against Starboard Value LP — but the drugmaker and its ...

As we move further into October, many investors may be looking to identify certain stocks with the potential to provide ...

Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its board on Tuesday as ...

W hat a twist! An activist investment fund, Starboard Value, has recently been pushing Pfizer (NYSE: PFE) to increase ...

In a previous interview, Lee hinted that a period of market volatility is expected, as 2024 heads for a soft landing.

The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...

Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...

Pfizer Inc. has won regulatory approval for its hympavzi drug as a treatment for hemophilia A or B without inhibitors - making it the first antitissue-factor pathway inhibitor to be allowed for the ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Pfizer (PFE – Research Report), with a price ...

Pfizer shares are on the up since US activist investor Starboard Value built up a stake in the drug maker. But strategic ...